Editorial Comment from Dr Miyake to Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART)

Int J Urol. 2024 Mar;31(3):273. doi: 10.1111/iju.15384. Epub 2024 Jan 3.
No abstract available

Publication types

  • Observational Study
  • Multicenter Study
  • Editorial

MeSH terms

  • Antibodies, Monoclonal, Humanized*
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Axitinib / adverse effects
  • Carcinoma, Renal Cell* / drug therapy
  • Carcinoma, Renal Cell* / pathology
  • Humans
  • Japan
  • Kidney Neoplasms* / drug therapy
  • Kidney Neoplasms* / etiology
  • Retrospective Studies

Substances

  • avelumab
  • Axitinib
  • Antibodies, Monoclonal, Humanized